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Abstract
Background: The mechanisms of progressive dopaminergic neuronal loss in Parkinson’s disease (PD) remain poorly
understood, largely due to the complex etiology and multifactorial nature of disease pathogenesis. Several lines of
evidence from human studies and experimental models over the last decade have identified neuroinflammation as a
potential pathophysiological mechanism contributing to disease progression. Tumor necrosis factor α (TNF) has
recently emerged as the primary neuroinflammatory mediator that can elicit dopaminergic cell death in PD. However,
the signaling pathways by which TNF mediates dopaminergic cell death have not been completely elucidated.
Methods: In this study we used a dopaminergic neuronal cell model and recombinant TNF to characterize intracellular
signaling pathways activated during TNF-induced dopaminergic neurotoxicity. Etanercept and neutralizing antibodies
to tumor necrosis factor receptor 1 (TNFR1) were used to block TNF signaling. We confirmed the results from our
mechanistic studies in primary embryonic mesencephalic cultures and in vivo using the stereotaxic lipopolysaccharide
(LPS) model of nigral dopaminergic degeneration.
Results: TNF signaling in dopaminergic neuronal cells triggered the activation of protein kinase Cδ (PKCδ), an isoform
of the novel PKC family, by caspase-3 and caspase-8 dependent proteolytic cleavage. Both TNFR1 neutralizing
antibodies and the soluble TNF receptor Etanercept blocked TNF-induced PKCδ proteolytic activation. Proteolytic
activation of PKCδ was accompanied by translocation of the kinase to the nucleus. Notably, inhibition of PKCδ signaling
by small interfering (si)RNA or overexpression of a PKCδ cleavage-resistant mutant protected against TNF-induced
dopaminergic neuronal cell death. Further, primary dopaminergic neurons obtained from PKCδ knockout (−/−) mice
were resistant to TNF toxicity. The proteolytic activation of PKCδ in the mouse substantia nigra in the
neuroinflammatory LPS model was also observed.
Conclusions: Collectively, these results identify proteolytic activation of PKCδ proapoptotic signaling as a key
downstream effector of dopaminergic cell death induced by TNF. These findings also provide a rationale for
therapeutically targeting PKCδ to mitigate progressive dopaminergic degeneration resulting from chronic
neuroinflammatory processes.
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Background
Parkinson’s disease (PD) is a debilitating neurodegenerative
movement disorder affecting around 2 % of the population
over the age of 60 [1,2]. The key pathological hallmark of
the disease is a loss of dopaminergic (DA) neurons in the
substantia nigra of the midbrain, resulting in a depletion of
striatal dopamine that is clinically manifest as a range of
motor and non-motor deficits [3]. Recent studies indicate
that a sustained neuroinflammatory response is initiated in
the substantia nigra pars compacta (SNpc) during early
stages of dopaminergic degeneration, and remains evident
in postmortem PD brains with increased microgliosis, dys-
trophic astrocytes and lymphocyte infiltration [4-6]. Com-
pelling evidence over the last decade from animal models,
in vitro studies and PD patients has demonstrated that the
protracted neuroinflammation that occurs in the SNpc can
exacerbate the degeneration of vulnerable dopaminergic
neurons. However, the molecular mediators and mechan-
isms underlying the neuroinflammatory processes remain
to be established.
Tumor necrosis factor α (TNF) has recently emerged as
an important neuroinflammatory mediator linked to
dopaminergic degeneration in PD. Increased levels of TNF
are present in the SNpc and the CSF of postmortem PD
patients, and genetic polymorphisms in the TNF gene
locus have been linked to the development of PD [7-12].
Increased TNF is also well documented in rodent and
nonhuman primate models of PD induced by neurotoxic
insults and in transgenic models [13,14]. Importantly,
ablation of TNF signaling using knockout mice for TNFα
or its receptors has been shown to attenuate 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopa-
minergic degeneration [15,16]. Furthermore, genetic or
pharmacological inhibition of soluble TNF signaling
with dominant negative mutants is protective against 6-
hydroxydopamine and lipopolysaccharide (LPS)-induced
dopaminergic degeneration in vivo [17,18]. Conversely, the
chronic expression of low levels of TNF in the substantia
nigra of rats induced by a viral vector causes progressive
dopaminergic degeneration with delayed motor deficits
[19]. Together, these independent findings strongly impli-
cate TNF in the progressive loss of dopaminergic neurons
in PD. However, the signaling mechanisms by which TNF
can mediate dopaminergic degeneration have not been
characterized.
Protein kinase Cδ (PKCδ), a member of the novel PKC
isoform family, is highly expressed in nigral dopamin-
ergic neurons [20]. Recent studies from our laboratory
and others have shown that PKCδ is proteolytically acti-
vated by caspase-3 during dopaminergic cell death and
that genetic or pharmacological targeting of PKCδ can
protect against dopaminergic degeneration in PD models
[21-24]. In this paradigm, increased oxidative stress
in dopaminergic neurons results in proteolytic activation
of PKCδ by caspase-3 downstream of the intrinsic mito-
chondrial apoptotic pathway. The proteolytic cleavage of
PKCδ by caspase-3 persistently activates the kinase as an
effector of dopaminergic cell death. However, PKCδ
activation by extrinsic neuroinflammatory mediators such
as TNF has not been studied and would be relevant to the
progression of PD by neuroinflammatory mechanisms.
Since TNF also activates caspase-3 by signaling through its
death receptors, we determined if PKCδ is proteolytically
activated during TNF-induced dopaminergic cell death
and in the mouse substantia nigra (SN). Our findings
herein identify PKCδ as a key downstream target of TNF
death receptor signaling in dopaminergic neurons and
demonstrate a novel link between neuroinflammatory
mechanisms and progressive dopaminergic degeneration.
Methods
Chemicals and reagents
RPMI, neurobasal medium, B27 supplement, fetal bovine
serum, L-glutamine, Sytox assay dye, IR-dye-tagged
secondary antibodies, penicillin, streptomycin and other
cell culture reagents were purchased from Invitrogen
(Gaithersburg, MD, USA). Recombinant rat TNF, LPS
(Escherichia coli 0111:B4) and cytosine arabinoside were
purchased from Sigma-Aldrich (St Louis, MO, USA).
Recombinant murine TNF and the tumor necrosis factor
receptor 1 (TNFR1) neutralizing antibody were from
R&D Systems (Minneapolis, MN, USA). Etanercept
(Enbrel) was purchased from Amgen, Inc. (Thousand
Oaks, CA, USA). Antibodies for rabbit PKCδ and
caspase-8 were from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA, USA). Tyrosine hydroxylase (TH)
antibody was purchased from Chemicon (Temecula, CA,
USA) and microtubule-associated protein 2 (MAP-2)
antibody from Cell Signaling Technologies (Beverly, MA,
USA). 32P-ATP was purchased from Perkin Elmer
(Boston, MA, USA) and the AMAXA Nucleofector kit
from Lonza (Basel, Switzerland). Caspase assay
substrates and inhibitors were purchased from MP
Biomedicals (Solon, OH, USA). The DNA fragmentation
assay kit was purchased from Roche Applied Science and
the Bradford protein assay kit was purchased from
Bio-Rad Laboratories (Hercules, CA, USA).
Culture and treatment paradigm for rat dopaminergic
N27 cells
The development and culture conditions of the N27
clonal dopaminergic cell line have been described previ-
ously [21,24,25]. Similar culture conditions were used in
this study. Briefly, cells were cultured in RPMI 1640
medium containing 10 % heat inactivated fetal bovine
serum, 2 mML-glutamine, penicillin (100 units/ml), and
streptomycin (100 μg/ml). Cells were maintained in a
humidified atmosphere of 5 % CO2 at 37°C. RPMI
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medium containing 2 % fetal bovine serum was used for
the TNF treatment. Cells were washed twice in 2 %
RPMI serum and then treated with the indicated doses
of recombinant rat TNF.
Primary mouse mesencephalic neuron cultures
Primary neurons were cultured from ventral mesenceph-
alon tissue of gestational 14-day (E14) mouse embryos,
as described previously [21,26] with some modifications.
The ventral mesencephalon was dissected under a
microscope and collected in ice-cold Dulbecco’s modi-
fied Eagle medium F-12 complete medium (DMEM-F12
supplemented with 10 % heat-inactivated fetal bovine
serum (FBS), 50 U/mL penicillin, 50 μg/mL strepto-
mycin, 2 mML-glutamine, 100 μM non-essential amino
acids, and 2 mM sodium pyruvate). The tissue was then
dissociated using trypsin-ethylenediaminetetra-acetic
acid (EDTA) (0.25 %) for 15 minutes at 37°C. Trypsiniza-
tion was stopped by adding an equal volume of DMEM-
F12 complete medium and dissociated tissue was washed
in the same medium to remove residual trypsin. The
DMEM-F12 medium was aspirated out and the tissue
triturated in neurobasal medium containing B-27 anti-
oxidant supplement, 500 μML-glutamine, 100 U/ml
penicillin, and 100 μg/ml streptomycin. After a single
cell suspension was obtained, cells were passed through
a 70 μm nylon mesh cell strainer to remove tissue debris
and aggregates. Cells were counted using a Beckman
Coulter ViCell XR automated cell counter and then pla-
ted at an equal density (0.8 × 106 cells per well) in 24 well
plates containing coverslips precoated with poly-D-lysine
(100 μg/ml). Cultures were maintained in neurobasal
medium with B-27 antioxidant supplements and cytosine
arabinoside (5 μM) was added to inhibit glial proliferation.
Cultures were grown in a humidified CO2 incubator (5 %
CO2, 37°C) and the medium was changed every 2 days.
Approximately 4-day-old to 5-day-old cultures were used
for treatment. The neuronal cultures were verified to be
around 98 % free of glial cells at the time of treatment by
using immunocytochemistry for MAP-2, glial fibrillary
acidic protein (GFAP) and ionized calcium binding
adaptor molecule 1 (iba1) as markers of neurons,
astrocytes and microglia, respectively [27]. For TNF
treatment, cultures were switched to serum-free neuroba-
sal medium without antioxidant supplements and treated
for 48 h. Recombinant murine TNF (30 ng/ml) was added
at the beginning of the treatment and re-added again 24 h
later. At the end of the treatment, primary cultures were
processed for TH immunocytochemistry and neurotrans-
mitter uptake assays.
DNA fragmentation and Sytox assays
DNA fragmentation was quantified using the Cell Death
Detection ELISA Plus assay kit (Roche Applied Science),
as described in our previous publications [21,22,24]. This
highly sensitive and reliable assay detects and quantifies
early changes in apoptosis based on the amounts of
histone-associated low molecular weight DNA released
into the cytoplasm of cells. Briefly, N27 cells were plated
in six-well plates at 0.8 × 106 cells/well and treated the
next day with TNF for 16 h. Cells were collected using a
cell scraper and centrifuged at 400 × g for 5 minutes. The
cells were gently lysed using the lysis buffer provided
with the kit. The lysate then was spun down again at
200 g for 10 minutes to pellet the nuclear fraction, and
the supernatant was collected and used to measure DNA
fragmentation according to the manufacturer's instruc-
tions for the ELISA protocol. The absorbance at 405 nm
was measured against an 2,2'-azino-bis(3-ethylbenzothia-
zoline-6-sulfonic acid (ABTS) solution as a blank (refer-
ence wavelength approximately 490 nm) using a
Synergy-2 Multi-Mode Microplate Reader (BioTek
Instruments, Inc). The absorbance values were normal-
ized to the amount of protein present in the lysates and
the data expressed as percent control. The Sytox cyto-
toxicity assay was performed using the Sytox green
dye (Molecular Probes). The assay is based on the
principle that live cells with intact plasma membranes
can exclude the Sytox dye, which selectively enters
cells with a compromised membrane and emits bright
green fluorescence on binding to DNA [28]. N27 cells
were grown in 24 well plates and 1 μM of the Sytox
dye was added at the time of treatment. Cells were
treated for 16 h with TNF and pretreated with eta-
nercept. The increase in green fluorescence, as a re-
sult of TNF cytotoxicity, was measured using a
fluorescence microplate reader (Spectramax Gemini,
Molecular Devices) at an excitation of 485 nm and
538 nm emission. Phase contrast and fluorescence
images of matching fields were captured on the same
cells to visualize the toxicity in N27 cells.
Caspase-3 enzymatic activity assays
Enzymatic assays for caspase-3 activity were performed as
described previously [22,24] using acetyl-DEVD-amino-4-
trifluoromethylcoumarin (Ac-DEVD-AFC, 25 μm) as the
fluorometric substrate for the reaction. N27 cells were
treated with TNF (30 ng/ml) for 6 h or pretreated with
etanercept (5 μg/ml) for 30 minutes. Following treatment,
100 μl of cell extract was incubated with 5 μl of the
fluorescence substrate and then incubated at 37°C for 1 h
while being protected from light. The fluorescence signal
generated upon cleavage of the AFC peptide substrate by
caspase-3 was measured at 510 nm with an excitation of
400 nm using a Synergy-2 Multi-Mode microplate reader.
Protein concentrations were determined using the
Bradford assay. Raw values were normalized using protein
concentrations and expressed as percent control.
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Confocal immunofluorescence microscopy for PKCδ
translocation
N27 dopaminergic cells were plated on poly-D-lysine
(100 μg/ml) coated coverslips in 24 well plates at
0.2 × 106 cells per well. The next day, the cells were
treated with 30 ng/ml of TNF for 6 h in 2 % serum
RPMI medium. Cells were fixed in 4 % paraformaldehyde
for 20 minutes and washed five times in PBS. The cells
were blocked and permeabilized with blocking buffer
(5 % goat serum, 0.2 % Triton X, and 0.05 % Tween-20
in PBS) for 1 h and then incubated overnight at 4°C with
a rabbit polyclonal PKCδ antibody (1:1,000) that recog-
nizes a C-terminal epitope present in both the native and
the proteolytically cleaved protein. The cells were then
washed five times in PBS and then incubated with
secondary antibody (1:2,000, Alexa 488 goat anti-rabbit)
for 1 h at room temperature. Negative controls for
non-specific staining that contained secondary antibody
alone were used on parallel wells to ensure specificity of
the fluorescent signals obtained. The cells were then
washed five times in PBS and the nucleus was labeled
using the TOPRO 3 dye. The cells were then washed
three more times in PBS and coverslips were mounted
using the ProLong Gold antifade reagent (Molecular
Probes). Confocal images were acquired with a Nikon
EZ-C1 confocal system using the 488 nm and 633 nm
lasers to visualize PKCδ and TOPRO 3, respectively.
Fluorescence spatial intensity plots along the XY plane
for PKCδ localization (green channel) and the nucleus
(blue channel) were generated using the Nikon EZC1
software to show nuclear translocation.
Fluorescent Western blotting
Lysates from N27 cells and brain tissue were prepared
using a modified radio immunoprecipitationassay (RIPA)
buffer and normalized for equal amounts of protein
using the BCA protein assay (Pierce Biotechnology). Gel
loading dye was added to the lysates and stored in
aliquots at −80°C. Equal amounts of protein (30 to 60 μg)
were loaded for each sample and separated on either 12 %
or 15 % SDS-PAGE gels, depending on the molecular
weight of the target protein. After separation, the proteins
were transferred to nitrocellulose membranes and non-
specific binding sites were blocked by incubating the
membranes in fluorescent Western blocking buffer
(Rockland Immunochemicals) for 1 h, and then they were
probed with primary antibodies overnight at 4°C. Primary
antibodies used were rabbit polyclonal PKCδ (1:500),
mouse monoclonal TH (1:2,000), rabbit polyclonal
caspase-8 (1:200). β-Actin (1:5,000) was used as the load-
ing control. After incubation, membranes were washed
three times with PBS containing 0.05 % Tween and IR-dye
tagged secondary antibodies (1:5,000; Molecular Probes)
were added. Membranes were visualized on the Odyssey
infra-red imaging system.
PKCδ immunoprecipitation (IP)-kinase assays
The PKCδ enzymatic kinase activity assay was performed
as described previously [21,22,29]. Briefly, N27 cells or
substantia nigra tissues were washed in ice-cold PBS and
then resuspended in a mild RIPA lysis buffer containing
protease and phosphatase inhibitor cocktail (Pierce
Biotechnology). The lysates were placed on ice for 20 min-
utes, sonicated gently and centrifuged at 13,000 rpm for
45 minutes. The supernatant was collected and protein
concentration was determined using the Bradford assay
[30]. All samples were made up to a concentration of
2 μg/ml, and 500 μg of total protein in a 250 μl volume
was immunoprecipitated overnight at 4°C using 5 μg of
the PKCδ antibody. The next day, the protein A-agarose
beads (Sigma-Aldrich) were added and the samples were
incubated for 1 h at room temperature. The protein
A-bound antibody complexes were then washed three
times in 2× kinase assay buffer (40 mM Tris, pH 7.4,
20 mM MgCl2, 20 μM ATP, and 2.5 mM CaCl2), and then
resuspended in 40 μl of the same buffer. The kinase
reaction was started by adding 40 μl of the reaction buffer
containing 0.4 mg of histone H1, 50 μg/ml phosphatidyl-
serine, 4 μM dioleoylglycerol, and 10 μCi of [γ-32P] ATP at
3,000 Ci/mM to the immunoprecipitated samples. The
samples were incubated for 10 minutes at 30°C. The
kinase reaction was stopped by adding 2×SDS loading
buffer and boiling the samples for 5 minutes. The proteins
were separated on a 12 % SDS-PAGE gel and the
phosphorylated histone H1 bands were scanned using a
Fujifilm FLA 5000 imager. Image analysis and band quan-
tification were performed using the Fujifilm Multigauge
software package (Fujifilm USA, Stamford, CT).
Transfection with siRNA and cleavage-resistant
PKCδD327A-CRM mutant
Design and synthesis of PKCδ siRNA are described in
our previous publications [21,31]. N27 cells were trans-
fected with 40 to 50 nM of either PKCδ or scramble
siRNA duplexes using the AMAXA Nucleofector kit,
according to the manufacturer’s instructions. Transfected
cells were counted using a Vi-Cell XR automated cell
counter and seeded at equal density (0.5 × 106 cells/well)
into six-well plates. The cells were treated 24 h after
transfection to allow for optimal knockdown of gene
expression. At the end of the treatment, cells were
collected and used for the DNA fragmentation assay as
described above. For studies with the PKCδ cleavage-
resistant mutant (PKCδD327A-CRM), stable N27 cell lines
overexpressing either the mutant PKCδD327A protein or
the β-galactosidase (Lac Z) protein as the vector control
were prepared as described in our publications [32]. Both
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cell lines were cultured in the presence of blasticidin for
three passages before treatment. Expression of the PKCδ
CRM-mutant and the Lac Z vector control at the time of
treatment was confirmed by staining for the V5-epitope.
Cells were plated at equal density (0.7 × 106 cells per
well) in six-well plates and allowed to grow overnight.
The next day, cells were treated with 30 ng/ml of TNF
for 16 h and processed for the DNA fragmentation assay.
Dopamine uptake assays
Uptake assays for tritiated dopamine on primary EVM
cultures were performed according to previously published
protocols [17,33,34]. After TNF treatment, the primary
neuron cultures from PKCδ wild type (+/+) and knockout
(−/−) mice were washed three times with 0.5 ml of warm
Krebs-Ringer buffer (16 mM sodium phosphate, 120 mM
NaCl, 4.7 mM KCl, 1.8 mM CaCl2, 1.2 mM MgSO4,
1.3 mM EDTA, and 5.6 mM glucose; pH 7.4). The cultures
were then incubated with 5 μM [3H]-dopamine (30 Ci/
mmol) in Krebs-Ringer buffer at 37°C for 20 minutes. The
cells were then washed three times with ice-cold
Krebs-Ringer buffer and collected in 1 ml of 1 N NaOH.
Scintillation fluid was added to a total volume of 5 ml and
radioactivity counts were measured using a Tri-Carb
Liquid Scintillation counter (Packard). In parallel wells,
the nonspecific uptake of dopamine was determined by
incubation with 10 μM mazindol. The nonspecific uptake
values were subtracted to obtain the data for high affinity
neurotransmitter uptake. Data from dopamine uptake
studies were expressed as percent control.
TH-positive cell counts and immunofluorescence
After TNF treatment, primary neuron cultures from
PKCδ wild type (+/+) and PKCδ knockout (−/−) mice
were fixed in 4 % paraformaldehyde and permeabilized
with PBS containing 2 % bovine serum albumin (BSA),
0.2 % Triton X-100 and 0.05 % Tween-20. Blocking
buffer (PBS with 2 % BSA) was added for 1 h at room
temperature and primary antibodies for TH (1:1,000)
and MAP-2 (1:1,000) were diluted in blocking buffer and
incubated overnight at 4°C. The next day, cells were
washed in PBS four times and incubated with appropri-
ate Alexa-dye conjugated secondary antibodies for 1 h at
room temperature. After several washes, the samples
were counterstained with Hoechst to label the nucleus,
and coverslips were mounted using the Prolong Antifade
(Molecular Probes) mounting medium. Images were
acquired using a Nikon inverted fluorescence microscope
(model TE-2000U) equipped with a SPOT digital camera
system (Diagnostic Instruments, Sterling Heights,
MI, USA). Image analysis was performed using the
Metamorph software package (Universal Imaging
Systems, PA, USA).
Stereotaxic infusion of LPS into the mouse substantia nigra
A single dose LPS injection model that was previously
described [35] was used to induce delayed, progressive
loss of dopaminergic neurons in the substantia nigra.
C57/BL/6 mice (8 weeks old, n = 6 per group) were
anesthetized with a mixture of ketamine-xylazine
(100 mg/kg, 10 mg/kg) and carefully immobilized on a
stereotaxic apparatus (Benchmark Angle One, Leica
Microsystems). The skin above the skull was prepped
with alcohol and an incision was made to expose the
skull. A single burr hole was carefully drilled at the injec-
tion site for the right SN and ophthalmic gel was used to
protect the eyes. The stereotaxic coordinates for the
injection site were anteroposterior (AP) -3.3 mm, medio-
lateral (ML) -1.2 mm, dorsoventral (DV) -4.6 mm from
bregma [36]. A stainless steel cannula attached to a 5 μl
Hamilton syringe was carefully inserted into the hole
drilled at the injection site and a single dose of 5 μg LPS
in a 1 μl volume was injected at the rate of 0.5 μl per mi-
nute. The needle was left in place for another 5 minutes
to prevent retrograde flow of liquid along the needle
track. Control mice were injected in an identical manner
with equal volumes of saline. After surgery, the skin was
sutured and carefully held in place using sterile, non-
pyrogenic stainless steel clips (Autoclip Wound Closing
System, Braintree Scientific, Inc). Mice were allowed to
recover on a heating pad (Braintree Scientific, Inc) and
were carefully monitored through recovery from
anesthesia. All animal procedures were approved by the
Iowa State University Institutional Animal Care and Use
Committee (IACUC).
Data analysis
Data analysis was performed using the Prism 4.0 software
package (GraphPad Software, San Diego, CA, USA). The
data were first analyzed using one-way analysis of variance
(ANOVA) and then Bonferroni’s post-test was performed
to compare all treatment groups. Differences of P <0.05
were considered statistically significant. The Student’s t
test was used when differences between two groups were
being compared.
Results
TNF is neurotoxic to dopaminergic N27 cells and activates
caspase-8 and caspase-3
To determine the downstream mechanisms underlying
TNF stimulation in dopaminergic neuronal cells, we
used the N27 dopaminergic neuronal cell model, which
has been widely used by several laboratories to study
dopaminergic degeneration related to PD [21,24,25]. First
we examined the neurotoxic effect of TNF on N27
dopaminergic neuronal cells. The Sytox assay and the
sensitive DNA fragmentation ELISA were used to
quantify TNF cytotoxicity. TNF (30 ng/ml) induced
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significant increases in Sytox fluorescence and cell death
morphology, which could be blocked using the TNF
neutralizing drug etanercept (Figure 1A,B). Since TNF
cytotoxicity can proceed through activation of caspases
in various cell types, we examined caspase activation
downstream of TNF signaling. High levels of the
pro-caspase-8 protein were detected in N27 cells, and
TNF treatment induced activation of caspase-8 at 3 h,
with increased accumulation of the active p20 fragment
(Figure 1C,D). Again, the activation of caspase-8 was
attenuated by pretreatment with the TNF inhibitor
etanercept. Since caspase-3 is an important effector
caspase downstream of TNF signaling, and is known to
be activated in PD models and in the human PD brain
[37,38], we studied caspase-3 activation in TNF-treated
N27 cells. We found that TNF treatment for 6 h caused
activation of caspase-3, which could be blocked by
pretreatment with etanercept and the caspase-8 inhibitor
IETD-fmk (Figure 1E). These results indicate that
caspase-3 is activated in a caspase-8 dependent manner
downstream of TNF death receptor signaling in dopa-
minergic neuronal cells. Next we used the sensitive DNA
fragmentation ELISA assay to quantify TNF cell-death
signaling. Exposure to TNF (30 ng/ml) for 16 h resulted
in a threefold increase in DNA fragmentation compared
to untreated controls (Figure 1F). Pretreatment with the
TNF-neutralizing drug etanercept or a caspase-8 inhibi-
tor (IETD-fmk) almost completely blocked TNF-induced
DNA fragmentation, indicating that canonical TNF death
receptor signaling through activation of caspase-8 is
involved in the dopaminergic neurotoxicity caused by
sustained exposure to TNF. In preliminary studies, we
found that doses as low as 10 ng/ml TNF could induce
detectable toxicity in N27 dopaminergic cells. We chose
a 30 ng/ml dose of TNF based on previous in vitro
studies [26] and because this concentration induced a
consistent neurotoxic response in vitro. The dose range
of TNF used in our mechanistic studies is high
compared to the levels of circulating TNF in the serum
and CSF of PD patients [39-41] due to the fact that high
doses are necessary to elicit a detectable response in cell
culture models within a shorter timeframe. Also, the
circulating TNF has a short half-life and therefore, it does
not reflect the elevated levels of tissue TNF in the
substantia nigra. The TNF concentration at 10 to 60 ng/ml
used in our study is consistent with doses used in cell
culture experiments by other researchers [17,26].
TNF induces proteolytic activation of protein kinase Cδ in
dopaminergic neuronal cells
We recently showed that PKCδ, a proapoptotic kinase
belonging to the novel PKC isoform family, is highly
expressed in dopaminergic neurons [21,42]. Further, we
demonstrated that PKCδ is activated by caspase-3
mediated proteolytic cleavage at its hinge region follow-
ing mitochondrial oxidative stress, resulting in persistent
activation of the kinase and amplification of apoptotic
signals in dopaminergic neurons [21,22,24]. Since PKCδ
activation by the extrinsic apoptotic pathway in dopa-
minergic cells or its role in neuroinflammation-induced
dopaminergic neurotoxicity has not been examined, we
tested if PKCδ can be activated by caspase-3 during
TNF-induced death of dopaminergic neuronal cells and
function as a downstream apoptotic effector. Interest-
ingly, TNF treatment caused a time and dose dependent
proteolytic activation of PKCδ that was detectable 3 h
after treatment and increased at 6 h (Figure 2A,B). Dose
response studies at the 6 h time point showed that doses
as low as 10 ng/ml of TNF could induce detectable
proteolytic activation of PKCδ, which increased substantially
with 30 ng/ml TNF. Higher doses of TNF (60 ng/ml) did
not significantly increase PKCδ cleavage further (Figure 2C,
D). Since caspase-8 and caspase-3 were activated by TNF in
these cells, we tested if PKCδ proteolytic activation was
mediated by this signaling pathway using the specific
caspase inhibitors DEVD-fmk and IETD-fmk. Pretreatment
with the caspase-8 and caspase-3 inhibitors suppressed
TNF-induced proteolytic activation of protein kinase Cδ
(Figure 2E,F). Taken together, these results suggest that the
proapoptotic kinase PKCδ could be activated by caspase-8
and caspase-3 dependent proteolytic cleavage during TNF
toxicity in dopaminergic neuronal cells. The proteolytically
cleaved PKCδ fragment appeared as a doublet band in
Western blots in our experiments. Several alternate splice
forms of PKCδ have been reported, including a caspase-3
cleavage-resistant form and a truncated form lacking the
regulatory domain [43,44]. Also, the C-terminal catalytic
domain of PKCδ contains multiple phosphorylation sites.
Because the antibody used in these studies recognizes the
C-terminal catalytic domain, it is possible that the doublet
band of the cleaved product represents a post-translational
modification of the cleavage product or one of the truncated
PKCδ alternate splice forms.
Proteolytic activation of PKCδ by TNF signaling activates
the kinase
Unlike other proteins for which proteolytic cleavage can
result in loss of function or inactivation, the proteolytic
cleavage of PKCδ by caspase-3 during oxidative stress-
induced dopaminergic cell death has been shown to
persistently activate the kinase [21,22,24,45]. We used
IP-kinase assays and Western blotting to determine if
TNF-induced proteolytic activation of PKCδ leads to
sustained activation of the kinase in N27 dopaminergic
cells. As shown in Figure 3A, treatment with TNF for
6 h significantly increased proteolytic cleavage of PKCδ,
which was blocked by pretreatment with Etanercept or a
TNFR1 receptor-neutralizing antibody. PKCδ IP-kinase
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Figure 1 Tumor necrosis factor (TNF)-induced neurotoxicity and caspase activation in N27 dopaminergic neuronal cells. (A) Visualization of
TNF toxicity by Sytox fluorescence cytotoxicity assay. N27 dopaminergic cells treated with TNF (30 ng/ml), or pretreated with etanercept (5 μg/ml) for
30 minutes and were processed for Sytox green imaging at 16 h. Increased green fluorescence is evident with TNF treatment, indicating significant
neurotoxicity which was also evident in the phase contrast images. (B) Sytox fluorescence was quantified by measuring the fluorescence intensity as
relative fluorescence units (RFU) using a plate reader. (C) Activation of caspase-8 by TNF treatment. Lysates from N27 cells treated with TNF (30 ng/ml)
for 3 h were probed using a rabbit polyclonal antibody to caspase-8 that detects the procaspase and the active cleaved form. TNF induced a
significant increase in the active caspase-8 (p20) fragment, which was blocked by pretreatment with etanercept (5 μg/ml). (D) Band intensities for
cleaved caspase-8 from three blots were quantified using densitometric analysis and normalized to β-actin. (E) TNF induced activation of caspase-3.
Enzymatic assays for caspase-3 activity in lysates from N27 cells treated with TNF (30 ng/ml) for 6 h or pretreated with either etanercept (5 μg/ml) or
the caspase-8 inhibitor IETD-fmk (25 μM) for 30 minutes. Raw values were normalized using protein concentrations and expressed as percent control.
TNF treatment induced significant activation of caspase-3, which was blocked by etanercept and the caspase-8 inhibitor IETD-fmk. (F) TNF-induced
DNA fragmentation. N27 cells were treated with TNF (30 ng/ml) for 16 h or pretreated for 30 minutes with either etanercept (5 μg/ml) or the caspase-8
peptide inhibitor IETD-fmk (25 μM), and processed for the DNA fragmentation assay. Raw values were normalized using protein concentration and
expressed as percent control. TNF treatment significantly increased DNA fragmentation, which was attenuated by etanercept or caspase-8 inhibition.
Data represent the group mean± SEM; n= 6 to 8 per group and experiments were repeated three times. ** (P <0.01) indicates significant differences
compared to control cells; ## (P <0.01) and # (P <0.05) indicates significant differences compared to TNF-treated cells.
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Figure 2 Tumor necrosis factor (TNF) induced proteolytic cleavage of protein kinase Cδ (PKCδ) in dopaminergic N27 cells. (A) Time-dependent
PKCδ proteolytic activation. N27 dopaminergic cells were treated with recombinant TNF (30 ng/ml) for 3 h and 6 h and lysates were probed by
Western blotting with an antibody to the C-terminus that detects both the native protein (78 kDa) and the proteolytically cleaved catalytic
fragment (38 kDa). TNF treatment caused a time-dependent increase in PKCδ cleavage, which peaked at 6 h. (B) Band intensities for cleaved PKCδ
from three blots quantified using densitometric analysis and normalized to β-actin. (C) Dose-dependent proteolytic activation of PKCδ by TNF
treatment. N27 cells were treated with increasing doses of TNF (0 to 60 ng/ml) for 6 h and lysates were probed for PKCδ by Western blotting. TNF
induced a dose dependent increase in PKCδ cleavage, starting at 10 ng/ml. (D) Band intensities for cleaved PKCδ from three blots were quantified
using densitometric analysis and normalized to β-actin. (E) Caspase-3 and caspase-8 dependent proteolytic cleavage of PKCδ. N27 cells were
treated with 30 ng/ml of TNF alone for 6 h or in the presence of peptide inhibitors (25 μM) of caspase-8 (Ac-IETD-fmk) and caspase-3
(Ac-DEVD-fmk). Lysates were probed for PKCδ proteolytic cleavage by Western blotting. Proteolytic activation of PKCδ by TNF treatment was
reduced by inhibition of caspase-3 and caspase-8. (F) Band intensities for cleaved PKCδ from three blots were quantified using densitometric
analysis and normalized to β-actin. Data is expressed as a fold change over control. * (P <0.05) and ** indicate significant differences compared to
control cells; # (P <0.05) indicates significant differences compared to TNF-treated cells.
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assays performed in the absence of lipid cofactors
showed a robust increase in PKCδ kinase activity in
TNF-treated samples, which could be attenuated by pre-
treatment with etanercept or by TNFR1 receptor
neutralization (Figure 3C). These results demonstrate for
the first time that PKCδ can be proteolytically activated
in dopaminergic cells by a TNFR1-dependent signaling
pathway, resulting in sustained activation of the kinase
during TNF-induced cell death.
PKCδ translocates to the nucleus during TNF-induced
cell death
Nuclear translocation of PKCδ has been shown to occur
following proteolytic activation by apoptotic stimuli. A
bipartite nuclear localization sequence (NLS) has been
identified at the C-terminus (amino acids 611 to 623) of
PKCδ [46,47]. The NLS is required for nuclear localization
of both the full-length and proteolytically-cleaved forms
of PKCδ. However, previous studies have shown that
Figure 3 Proteolytic cleavage and activation of protein kinase Cδ (PKCδ) downstream of tumor necrosis factor receptor 1 (TNFR1) in
N27 dopaminergic cells. (A) TNFR1-dependent proteolytic activation of PKCδ. N27 cells were treated with tumor necrosis factor (TNF) (30 ng/ml)
for 6 h or pretreated with either a TNFR1 neutralizing antibody (TNFR1-nAb, 20 μg/ml) or etanercept (5 μg/ml) for 30 minutes and lysates were
probed for PKCδ proteolytic cleavage by Western blotting. TNF induced strong proteolytic cleavage of PKCδ that could be blocked by neutralizing
TNFR1 receptor signaling. (B) Band intensities for cleaved PKCδ were quantified using densitometric analysis and normalized to β-actin levels. (C)
Immunoprecipitation (IP)-kinase assay for PKCδ activation. IP-kinase assays were performed on the same cell lysates used for Western blots. PKCδ
was immunoprecipitated from 500 μg of total protein from each sample and used for the in vitro kinase activity assay with a histone substrate
and radiolabeled [γ-32P] ATP. PKCδ activity was quantified using densitometric analysis of the 32P-histone band intensity and expressed as percent
control. The proteolytic cleavage of PKCδ induced by TNF treatment was accompanied by a concomitant increase in kinase activity and was
dependent on signaling through the TNFR1 receptor. A representative kinase assay gel is shown. Data represent the group mean± SEM of
densitometric values obtained from three independent experiments. *** (P <0.001) denotes significant differences compared to control cells and
## (P <0.01) denotes significant differences compared to TNF-treated cells.
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proteolytic activation of PKCδ by caspase-3 facilitates
unmasking of the NLS, resulting in increased nuclear
translocation of the catalytic fragment during apoptosis
[47-49]. To further characterize the role of PKCδ in
dopaminergic cell death induced by TNF, we used
confocal microscopy to study the subcellular localization
of PKCδ. N27 cells were treated with TNF for 6 h, the
time point at which the highest level of cleaved PKCδ
was detected, and confocal immunofluorescence was
used to visualize the subcellular localization of PKCδ.
We detected prominent nuclear localization of PKCδ
after 6 h in TNF-treated cells, while in control cells
PKCδ localized in the cytoplasm (Figure 4A). Nuclear
translocation was also clearly evident in spatial fluores-
cence signal intensity plots (Figure 4B) for PKCδ (green
channel) and the Hoechst nuclear stain (blue channel).
Control cells had spatially distinct fluorescence signals
for the nucleus and PKCδ, showing that PKCδ is largely
localized outside the nucleus. However in TNF-treated
cells, the spatial fluorescence signals had the same pat-
tern along the XY plane. Interestingly, in addition to
the overall increase in nuclear localization with TNF
treatment, we also observed punctuate staining of PKCδ
at distinct locations around the perinuclear region
(shown in 60 ×magnification and labeled with red
arrows). The nuclear localization of PKCδ following
Figure 4 Protein kinase Cδ (PKCδ) translocates to the nucleus during tumor necrosis factor (TNF) treatment. (A) Confocal imaging of
PKCδ localization. N27 cells were treated with TNF for 6 h and processed for immunocytochemistry using a rabbit polyclonal antibody that
recognizes both the native and cleaved form of PKCδ. An Alexa-488 dye-tagged secondary antibody was used to visualize PKCδ (green), and the
nucleus was stained using the TOPRO-3 dye (blue). In untreated controls (top panel), PKCδ was distinctly localized to the cytosol. In TNF-treated
cells (lower panel), a distinct localization of PKCδ to the nucleus and the perinuclear region is seen. Scale bars are 20 microns. High magnification
images (right panel) of PKCδ immunofluorescence staining in N27 cells showing PKCδ accumulation within the nucleus and at distinct spatial
locations at the perinuclear region following TNF treatment (red arrows). Representative images are shown; experiments were repeated three
times using different secondary antibodies for validation. (B) Fluorescence spatial intensity plots along a representative XY plane for PKCδ
localization (green channel) and the nucleus (blue channel) were obtained using the Nikon EZC1 image analysis software. Control images show a
distinct spatial localization of green and blue fluorescence intensities in the XY plane indicative of cytosolic PKCδ localization. In TNF-treated cells
a spatial colocalization of green and blue fluorescence signals is evident indicating nuclear translocation of PKCδ.
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TNF treatment further points to an important role
for this kinase in dopaminergic degeneration during
TNF toxicity.
Overexpression of a cleavage-resistant mutant
(PKCδD327A-CRM) or siRNA knockdown of PKCδ protects
against TNF-induced dopaminergic cell death
To determine whether TNF-induced PKCδ activation
contributes to the cell death process in dopaminergic cells,
we used siRNA suppression of PKCδ and a caspase-3
cleavage-resistant mutant of PKCδ (PKCδD327A-CRM).
First, N27 cells were transfected with siRNA to PKCδ or
scramble siRNA and incubated for 24 h to allow for
optimal suppression of PKCδ protein levels, which we vali-
dated by Western blotting (Figure 5B). The transfected
cells were then treated with TNF for 16 h and processed
for the DNA fragmentation assay. In N27 cells transfected
with scramble siRNA, TNF caused a significant increase in
DNA fragmentation, while the PKCδ siRNA transfected
cells were protected from cell death (Figure 5A). These
results indicate that PKCδ is required for TNF-induced
apoptosis in dopaminergic cells and that genetic or
pharmacological modulation of PKCδ may effectively
attenuate TNF-induced neurotoxicity. To evaluate the
significance of the PKCδ proteolytic cleavage events
during proapoptotic TNF signaling, we used N27 cells
Figure 5 Knockdown of protein kinase Cδ (PKCδ) with siRNA and overexpression of the PKCδ proteolytic cleavage-resistant mutant
(PKCδD327A-CRM) protects against tumor necrosis factor (TNF) toxicity. (A) DNA fragmentation assay in siRNA transfected cells. N27 cells
transfected with either siRNA to PKCδ or scrambled control siRNA were treated with TNF for 16 h and processed for the DNA fragmentation
ELISA. Raw values were normalized to protein concentrations and expressed as the fold change over the respective controls. TNF-induced DNA
fragmentation was significantly reduced in PKCδ siRNA transfected cells. (B) Suppression of the PKCδ protein levels by siRNA was confirmed by
Western blotting. (C) DNA fragmentation assay in N27 cells overexpressing the cleavage-resistant PKCδ mutant protein (PKCδD327A-CRM). N27 cells
stably expressing the cleavage-resistant PKCδ mutant or the β-galactosidase (LacZ) control gene were treated with TNF for 16 h and processed for
the DNA fragmentation assay. Expression of the mutant PKCδ protein was confirmed by imaging the V5 tag by immunocytochemistry. (D) DNA
fragmentation induced by TNF was attenuated in N27 cells expressing the caspase-3 cleavage-resistant mutant protein, indicating the proteolytic
cleavage is a necessary event for TNF toxicity in these cells. Data represent the group mean± SEM, n = 6 to 8 per group and experiments were
repeated three times. *** (P <0.001) indicates significant differences with TNF treatment compared to controls in scramble siRNA and LacZ
expressing cells; ## (P <0.01) indicates significant differences between the two TNF treatment groups.
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overexpressing a mutant PKCδ protein resistant to proteo-
lytic cleavage (PKCδD327A-CRM) by caspase-3 due to a
point mutation at the cleavage site. N27 cells that stably
express either the cleavage-resistant PKCδ mutant or the
LacZ protein (Figure 5D) were established as described
previously [32]. The cells were treated with TNF for 16 h
and processed for DNA fragmentation. As shown in
Figure 5C, TNF treatment caused a 2.5-fold increase in
DNA fragmentation in LacZ cells, while cells expressing
the PKCδD327A-CRM mutant were protected from TNF
toxicity, indicating that proteolytic cleavage of PKCδ is
crucial for TNF-induced cell death. Together, these results
demonstrate that PKCδ functions as a proapoptotic kinase
during TNF-induced dopaminergic neurotoxicity and that
proteolytic cleavage of PKCδ by caspase-3 downstream of
TNF signaling is required for cell death.
Primary dopaminergic neurons obtained from PKCδ
knockout (−/−) mice are protected from TNF neurotoxicity
In order to extend our results from the previous mech-
anistic studies with the dopaminergic N27 clonal cell
model to dopaminergic neurons, we used primary mouse
ventral mesencephalic dopaminergic neuron cultures.
We established primary mesencephalic neuronal (>95 %
glial-free) cultures from PKCδ wild type (+/+) and
knockout (−/−) mice to study the role of PKCδ in
mediating TNF-induced dopaminergic neurodegeneration.
Dopaminergic neurotoxicity was assessed by dopamine
uptake assays and by TH-positive cell counting. As shown
(Figure 6B,C), TNF exposure caused around 50 % decrease
in dopamine uptake and TH-positive cell counts in
cultures from PKCδ wild type (+/+) mice, consistent with
previous reports of dopaminergic neurotoxicity in similar
model systems [17,26]. However, in primary neuron
cultures obtained from PKCδ knockout (−/−) mice, TNF
induced only around a 20 % reduction in dopamine uptake
and TH-positive neuron counts, indicating that dopamin-
ergic neurons from PKCδ knockout mice were resistant to
TNF toxicity. In addition to functional measurement
of TNF neurotoxicity by dopamine uptake, we also
performed double labeling immunofluorescence morpho-
metric analysis using TH as a marker for dopaminergic
neurons and MAP-2 as a pan-neuronal marker. Untreated
cultures from both PKCδ wild type (+/+) and knockout
(−/−) mice had similar numbers of dopaminergic neurons
and displayed extensive branched neurites and normal
cell bodies (Figure 6A). In TNF-treated cultures, fewer
TH-positive neurons with smaller cell bodies and a clear
loss of neurites were evident in cultures from PKCδ wild
type (+/+) mice. In contrast, dopaminergic neurons in
cultures from PKCδ knockout (−/−) mice displayed visible
branched neurites and more numerous cell bodies
with normal morphology (Figure 6A lower panel),
demonstrating significant protection against TNF toxicity
in these cultures.
PKCδ is activated by proteolytic cleavage in the mouse
substantia nigra following stereotaxic infusion of LPS
Next, we sought to extend the significance of our results
obtained with the N27 dopaminergic cell culture model
and primary neurons to an in vivo model of dopaminergic
degeneration relevant to neuroinflammation. We selected
the widely used stereotaxic LPS injection model of
neuroinflammation-induced dopaminergic degeneration
for our experiments [17,35,50,51]. In this model, a single
injection of LPS into the rodent substantia nigra elicits a
sustained, localized neuroinflammatory response resulting
in a delayed loss of dopaminergic neurons in the SNpc.
We stereotaxically injected C57bl6 mice with a single dose
of 5 μg LPS into the substantia nigra and sacrificed them
14 days later, the time at which significant dopaminergic
degeneration occurs in this model [35]. The SN tissue was
dissected and probed for proteolytic activation of PKCδ
using Western blotting and IP-kinase assays. As shown in
Figure 7A, mice that received saline injections did not
show proteolytic activation of PKCδ in the SN, while LPS-
injected mice showed strong proteolytic cleavage of PKCδ
at 14 days. The PKCδ Western blots were reprobed for
tyrosine hydroxylase to confirm dissection of the substan-
tia nigra region. As expected, the LPS-injected mice had
decreased TH protein levels (Figure 7A), indicative of
increased dopaminergic degeneration in this model at
14 days [35,50]. We also used PKCδ IP-kinase assays with
a histone substrate on nigral tissue samples from LPS-
injected and saline-injected mice. In nigral tissues from
LPS-injected mice, we detected substantially higher PKCδ
kinase activity compared to saline injected controls
(Figure 7C), demonstrating that the proteolytic cleavage of
PKCδ resulted in activation of the kinase in vivo. Equal
protein loading and accurate dissection of the nigral tissue
was confirmed by Western blotting for β-actin and TH,
respectively. Together, these results demonstrate for the
first time that protein kinase Cδ can be activated by
proteolytic cleavage in the substantia nigra following LPS-
induced neuroinflammation.
Discussion
In this study, we identify PKCδ as a novel signaling
mediator downstream of TNF-induced toxicity in dopa-
minergic neurons and demonstrate that proteolytic
activation of PKCδ regulates dopaminergic degeneration
induced by TNF (Depicted schematically in Figure 8).
We also demonstrate for the first time, the proteolytic
activation of PKCδ in the mouse substantia nigra by
neuroinflammatory mechanisms during LPS-induced
dopaminergic degeneration. The proteolytic activation of
PKCδ by neuroinflammatory insults via the extrinsic
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apoptotic pathway has not been studied, therefore it is es-
sential to elucidate the mechanisms underlying progressive
degeneration of dopaminergic neurons by chronic neuroin-
flammatory processes involving TNF and other neurotoxic
mediators [52,53]. Based on the substantial literature sup-
porting a degenerative role for TNF during dopaminergic
cell death in PD models, we hypothesized that PKCδ can
be proteolytically activated downstream of canonical TNF
death receptor signaling by caspase-3 in dopaminergic neu-
rons. Since proteolytic cleavage of PKCδ by caspase-3 typ-
ically results in persistent activation of the kinase as an
apoptotic effector, we reasoned that blocking proapoptotic
PKCδ signaling could protect against TNF toxicity.
The results from our mechanistic studies using N27
rat dopaminergic cells indeed demonstrate for the first
time that soluble TNF induces a time-dependent and
dose-dependent proteolytic cleavage of PKCδ by a
caspase-8 and caspase-3 signaling pathway, indicative of
canonical TNF death receptor signaling via caspase-8.
Using the anti-TNF drug Etanercept and neutralizing
antibodies to the TNFR1 (p55) death receptor, we show
that proteolytic cleavage of PKCδ by soluble TNF is
dependent on TNFR1 signaling and is accompanied by a
substantial increase in PKCδ kinase activity (Figure 3),
consistent with proteolytic activation. Previous reports
from our laboratory and other independent research
Figure 6 Primary dopaminergic neurons in EVM cultures from protein kinase Cδ knockout (PKCδ −/−) mice are protected against
tumor necrosis factor (TNF) toxicity. Primary mouse EVM neuronal cultures were treated with recombinant TNF (30 ng/ml) in supplement-free
neurobasal medium. TNF was re-added 24 h later for a total treatment time of 48 h. PKCδ wild-type (PKCδ +/+) and knockout (PKCδ −/−) EVM
cultures were treated in parallel. (A) Immunocytochemistry for tyrosine hydroxylase (TH)-positive neurons. Dopaminergic neurons were identified
by TH staining (green) and microtubule-associated protein 2 (MAP-2) (red) was used as a pan-neuronal marker. Images were acquired at
20 ×magnification. Representative fields are shown for each treatment. In the TNF-treated group, extensive loss of neurites and degeneration of
dopaminergic neurons is evident in cultures from PKCδ wild-type (+/+) mice (top panel) whereas cultures from PKCδ knockout (−/−) mice had
visible branched neurites, more numerous cell bodies and were resistant to degeneration induced by TNF (lower panel). (B,C) TH-positive neuron
counts and dopamine uptake assays. (B) Dopaminergic neurons were identified by tyrosine hydroxylase labeling, and the number of TH-positive
neurons from 12 random fields per well were counted at 20 ×magnification for each treatment group. (C) The uptake of tritiated [3 H] dopamine
was determined in cultures from PKCδ wild-type (WT) and knockout mice. The values for non-specific uptake of dopamine obtained in the
presence of mazindol were subtracted as background and the data expressed as percent control. Data represent the group mean± SEM, n = 4 to
6 per group and experiments were repeated three times. ***P <0.001 indicates a significant difference between control and TNF-treated groups
in PKCδ wild type cultures. # (P <0.05) and ## (P <0.01) indicate a significant difference between TNF-treated groups in PKCδ wild-type and PKCδ
knockout (−/−) cultures.
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groups have shown that PKCδ proteolytic activation
contributes to apoptosis induced by diverse neurotoxic
stimuli that converge on the intrinsic mitochondrial
apoptotic pathway primarily through intracellular
oxidative stress mechanisms [21-24,31,32,54-56]. Taken
together, our present results suggest that proteolytic
activation of PKCδ could be a common effector of cell
death via both intrinsic and extrinsic cascades in
dopaminergic neurons.
Rapid and dynamic translocation to distinct subcellular
locations following activation is a characteristic feature
of PKCδ in different cell types, and typically delineates
the unique functional role of this kinase [57]. Various
substrates have been identified as targets of PKCδ
phosphorylation in different subcellular locations that
participate in a range of multiple cellular functions, from
apoptosis to cell migration and activation of immune
cells [58]. In particular, studies have demonstrated that
Figure 7 Proteolytic activation of protein kinase Cδ (PKCδ) in the mouse substantia nigra during LPS-induced dopaminergic
degeneration. C57BL/6 mice were stereotaxically injected with a single dose of lipopolysaccharide (LPS) (5 μg) or saline in the substantia nigra
(SN) to elicit dopaminergic degeneration. Mice were sacrificed after 14 days. (A) Proteolytic cleavage of PKCδ in mouse substantia nigra tissue.
Western blots were performed on nigral tissue lysates obtained from mice stereotaxically injected with either LPS or saline. Strong proteolytic
cleavage of PKCδ is seen in LPS-injected mice and was essentially absent in the saline-injected animals. Blots were also probed for tyrosine
hydroxylase and β-actin to confirm accurate dissection of the nigral tissue and equal protein loading respectively. (B) PKCδ cleaved band intensity
was quantified by densitometric analysis after normalization to β-actin (n = 4 to 6 mice per group). (C) PKCδ kinase activity in mouse substantia
nigra tissue. PKCδ IP-kinase assays were performed on nigral tissue lysates. Kinase activity was quantified by densitometric analysis of the 32P-
histone bands (n = 4 mice per group). A representative kinase gel is shown. Western blots of tyrosine hydroxylase and β-actin were performed on
the same lysates to verify accurate dissection of the nigral tissue. Data represent the group mean± SEM. ** (P <0.01) indicates a significant
difference between saline and LPS-injected mice.
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nuclear translocation of PKCδ is required for induction
of apoptosis and is driven by a bipartite nuclear
localization sequence at its C-terminus [48,49,59]. Our
confocal immunofluorescence experiments reveal a
distinct localization of PKCδ to the nucleus 6 h after
TNF treatment, the time point at which maximum
proteolytic cleavage of PKCδ was evident, consistent
with its proapoptotic function (Figure 4). While intense
PKCδ staining is evident throughout the nucleus in
TNF-treated cells, there is also a distinct pattern of accu-
mulation of PKCδ at specific sites around the perinuclear
region and within the nucleus. Interestingly, in a previ-
ous study, TNF superfamily ligands, such as BAFF (B
cell-activating factor belonging to the TNF family), have
been shown to prevent nuclear accumulation of full
length PKCδ and thus prolong cell survival in B cells
[60]. The substrates of PKCδ and the functional signifi-
cance of nuclear localization of the kinase during
neuroinflammation are currently under investigation
in our laboratory. However, the kinetics of PKCδ proteo-
lytic activation and its translocation to the nucleus
observed in our present study, both indicate of a
Figure 8 Schematic of protein kinase Cδ (PKCδ) activation by proteolytic cleavage downstream of tumor necrosis factor (TNF) signaling
in dopaminergic neurons. (1) Sustained TNF signaling leads to caspase-8 activation, presumably by autoproteolytic cleavage at the receptor
complex (2). Active caspase-8 leads to downstream activation of caspase-3, which can be blocked by the caspase-8 inhibitor IETD-fmk (3).
Caspase-3 activates PKCδ by proteolytic cleavage (4) at the hinge region (shown in red), releasing the catalytic fragment and causing constitutive
activation of the kinase (5). The constitutively active PKCδ catalytic fragment mediates proapoptotic signaling by phosphorylation of its
downstream substrates, resulting in DNA fragmentation and dopaminergic cell death (6). Blocking the PKCδ signaling pathway using siRNA,
targeted gene knockout or a caspase-3 cleavage-resistant mutant can protect against dopaminergic cell death induced by TNF toxicity.
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proapoptotic role for PKCδ downstream of TNF. Indeed,
suppressing total PKCδ protein levels using siRNA
or blocking proteolytic activation using a PKCδ cleavage-
resistant mutant (PKCδD327A-CRM) affords robust
protection against TNF neurotoxicity (Figure 5). The
results from our mechanistic studies are further
supported by our experiments in primary mesencephalic
neuronal cultures treated with soluble TNF, which
induces degeneration of dopaminergic neurons in these
cultures [17,26]. Although TNF was less toxic to primary
dopaminergic neurons than the classical Parkinsonian
neurotoxicant 1-methyl-4-phenylpyridinium (MPP+)
[21], we observed a substantial reduction in TH neuron
numbers and functional impairment as determined by
dopamine uptake studies in cultures from PKCδ wild
type (+/+) mice (Figure 6). Importantly, dopaminergic
neurons in mesencephalic cultures obtained from PKCδ
knockout (−/−) mice were protected against TNF
toxicity, indicating that PKCδ signaling is essential for
dopaminergic degeneration triggered by TNF.
Evidence from previous studies [17,26] and our own
results here, indicate that TNF can induce dopaminergic
neurotoxicity by a direct mechanism, possibly via the
TNFR1 (TNFRSF1) death receptor, which has been
shown to be highly expressed on these cells. However,
additional lines of evidence suggest that TNF can also
contribute to dopaminergic degeneration indirectly by
potentiating microglial reactive oxygen species (ROS)
and other neurotoxic mediators, which can increase local
oxidative stress levels in the SNpc [19,52,61]. The
elevated TNF levels in the SN in both animal models
and human PD patients and the concomitant microglial
activation indicate that potentiation of microglial neuro-
toxic responses by TNF likely occurs in vivo, although it
may not be the primary mechanism of dopaminergic
neurotoxicity, as suggested by McCoy et al. using mixed
neuron-glial cultures. A chronic increase in TNF levels
in the nigrostriatal system may drive the progressive loss
of compromised and vulnerable dopaminergic neurons
in the pro-oxidant environment of the SNpc, both by
TNF apoptotic signaling and by potentiation of micro-
glial neurotoxic responses, including ROS and RNS
production [17,19,26,52,62]. Nonetheless, our data
demonstrating that PKCδ is proteolytically activated in the
substantia nigra in the neuroinflammatory LPS model
(Figure 7) of PD, implicate proapoptotic PKCδ signaling
as a common downstream effector of dopaminergic
cell death triggered by convergent neuroinflammatory
mechanisms involving TNF and other neurotoxic media-
tors in the mouse brain.
Conclusions
Despite extensive research into the etiology of PD for
several decades, a cogent basis for the vulnerability and
extensive loss of SNpc dopaminergic neurons still
remains elusive. The emerging consensus is that PD
results from complex interactions between environmen-
tal, genetic and cellular processes that induce dopamin-
ergic cell death over time [3,63]. This highlights the
multifactorial nature of the disease process and
underscores the importance of identifying therapeutic
targets that are relevant across these multiple mechan-
isms of disease pathogenesis. While oxidative stress,
mitochondrial dysfunction and proteasomal impairment
have been identified as causative factors that can trigger
dopaminergic cell death; reactive microgliosis and
dysregulated neuroinflammation can sustain this process
and result in progressive neurodegeneration [6,52,53].
We previously showed that proteasomal impairment,
mitochondrial dysfunction and oxidative stress induce
proteolytic activation of PKCδ to drive dopaminergic cell
death [24,45,64]. Our results herein suggest a crucial role
for proapoptotic PKCδ signaling during dopaminergic
cell death induced by extracellular TNF and
neuroinflammatory mechanisms. Pharmacological target-
ing of PKCδ with kinase inhibitors such as rottlerin has
shown efficacy in protecting against dopaminergic
degeneration in vitro and in the MPTP mouse model of
PD [21,55]. Our results from this study provide a
rationale for pharmacological targeting of PKCδ to
mitigate neuroinflammatory events associated with
progressive degeneration of dopaminergic neurons in
PD. Taken together, our results herein suggest that
proteolytic activation of PKCδ could be a common
downstream target for multiple mediators of dopamin-
ergic degeneration by both extrinsic and intrinsic cell
death mechanisms, making it an attractive therapeutic
target during the progressive phase of PD.
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